Physician Assistant, Medical · Nashville, TN
NPI
1043220320
Since 2006
Specialty
Physician Assistant, Medical
Code 363AM0700X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1211 21st Ave S, 220 Medical Arts Building
Nashville, TN, 37232
Phone (615) 322-0128
Groups this clinician bills Medicare through
Medicare paid, 2024
$11K
282 services
Medicare patients, 2024
94
Average age 65
Drug cost, 2024
$1.4M
601 prescriptions
Company payments, 2025
$213
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kim A Annis was code 99214 (office e&m - established), 148 times for 85 patients. In total Kim A Annis billed 282 services in 7 codes, and Medicare paid $11K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 148 | 85 | $62.57 | $9,260 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 116 | 74 | $10.53 | $1,221 |
By year: 2022 $8,953 for 176 services; 2023 $8,646 for 164 services; 2024 $11K for 282 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kim A Annis prescribed most often to Medicare patients was Diphenoxylate-Atropine (Diphenoxylate Hcl/Atropine), with 57 prescriptions and refills. In total Kim A Annis wrote 601 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 57 | 60 | 16 | $2,366 |
| Mesalamine Generic | 44 | 92 | 14 | $29K |
| Loperamide Loperamide Hcl | 37 | 43 | Under 11 | $2,200 |
| Entyvio Vedolizumab | 36 | 40 | Under 11 | $300K |
| Balsalazide Disodium Generic | 29 | 83 | Under 11 | $13K |
| Dicyclomine Hcl Generic | 27 | 38 | Under 11 | $432 |
| Stelara Ustekinumab | 27 | 35 | Under 11 | $686K |
| Humira(Cf) Pen Adalimumab | 25 | 25 | Under 11 | $223K |
| Xifaxan Rifaximin | 25 | 25 | Under 11 | $67K |
| Sodium Chloride 0.9 % Sodium Chloride | 25 | 25 | Under 11 | $212 |
| Omeprazole Generic | 23 | 59 | 12 | $165 |
| Azathioprine Generic | 22 | 52 | Under 11 | $1,265 |
| Famotidine Generic | 22 | 42 | Under 11 | $123 |
| Pantoprazole Sodium Generic | 21 | 53 | Under 11 | $363 |
| Celecoxib Generic | 14 | 34 | Under 11 | $273 |
Brand drugs: 175 claims; generic drugs: 426 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kim A Annis $213 ($213 in general payments such as food, travel and fees) from 2 companies. The largest payer was Abbvie Inc. with $147.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.